[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571664":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":11,"centralContacts":44,"locations":50,"responsibleParty":70,"collaborators":74,"id":88,"slug":89,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":11,"eligibilityCriteria":94,"healthyVolunteers":90,"sex":95,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":11,"studyType":101,"phases":102,"briefSummary":104,"conditions":105,"keywords":11,"overallStatus":53,"whyStopped":11,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Shandong University","OTHER",[8,15,20],{"label":9,"type":10,"description":11,"interventionNames":12},"14-day dual regimen","ACTIVE_COMPARATOR",null,[13,14],"Drug: vonoprazan+amoxicillin","Other: Duration of eradication regimen: 14-day",{"label":16,"type":17,"description":11,"interventionNames":18},"10-day dual regimen","EXPERIMENTAL",[13,19],"Other: Duration of eradication regimen: 10-day",{"label":21,"type":17,"description":11,"interventionNames":22},"7-day quadruple regimen",[23,24],"Other: Duration of eradication regimen: 7-day","Drug: vonoprazan+amoxicillin+tetracycline+bismuth",[26,31,34,38,41],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"DRUG","vonoprazan+amoxicillin","Drug combinations for dual regimens：vonoprazan+amoxicillin",[16,9],{"type":6,"name":32,"description":32,"armGroupLabels":33,"otherNames":11},"Duration of eradication regimen: 7-day",[21],{"type":27,"name":35,"description":36,"armGroupLabels":37,"otherNames":11},"vonoprazan+amoxicillin+tetracycline+bismuth","Drug combinations for quadruple regimens: vonoprazan+amoxicillin+tetracycline+bismuth",[21],{"type":6,"name":39,"description":39,"armGroupLabels":40,"otherNames":11},"Duration of eradication regimen: 10-day",[16],{"type":6,"name":42,"description":42,"armGroupLabels":43,"otherNames":11},"Duration of eradication regimen: 14-day",[9],[45],{"name":46,"role":47,"phone":48,"phoneExt":11,"email":49},"Yanqing Li, Ph.D","CONTACT","+8653188369277","liyanqing@sdu.edu.cn",[51],{"facility":52,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Qilu Hospital of Shandong University","RECRUITING","Jinan","Shandong","250012","China","CN",{"type":60,"coordinates":61},"Point",[62,63],116.99722,36.66833,{"lat":63,"lon":62},[66],{"name":67,"role":47,"phone":68,"phoneExt":11,"email":69},"Yueyue Li","+86-18560089751","lyynqj@126.com",{"type":71,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Yanqing Li","Ph.D",[75,77,79,82,84,86],{"name":76,"class":6},"Zibo Maternal and Child Health Hospital",{"name":78,"class":6},"Zaozhuang Municipal Hospital",{"name":80,"class":81},"Feicheng Municipal People's Hospital","UNKNOWN",{"name":83,"class":6},"Shandong University of Traditional Chinese Medicine",{"name":85,"class":81},"The People's Hospital of Jimo.Qingdao",{"name":87,"class":6},"Dezhou Hospital Qilu Hospital of Shandong University","100571664","phase-4-efficacy-of-different-durations-of-dual-and-quadruple-regimens-for-helicobacter-pylori-eradication-100571664",false,"NCT06723197","Efficacy of Different Durations of Dual and Quadruple Regimens for Helicobacter Pylori Eradication","Efficacy of Different Durations of Dual and Quadruple Regimens for Helicobacter Pylori Eradication: a Multicentre, Randomised, Controlled Trial","Inclusion Criteria:\n\n1. Patients aged 18-70 years old\n2. Patients with H.pylori infection (13C\u002F14C-urea breath test)\n3. Patients without previous treatment for H. pylori eradication\n\nExclusion Criteria:\n\n1. Patients with serious underlying diseases, such as liver insufficiency (Aspartate aminotransferase or alanine aminotransferase greater than the normal value), renal insufficiency (Cr≥2.0mg\u002FdL or glomerular filtration rate \\\u003C50 ml\u002Fmin), immunosuppression, malignant tumors, Coronary heart disease or coronary artery stenosis ≥75%\n2. Patients with active gastrointestinal bleeding\n3. Patients with a history of upper gastrointestinal surgery\n4. Patients allergic to treatment drugs\n5. Patients with medication history of bismuth, antibiotics within 4 weeks, or proton pump inhibitor within 2 weeks\n6. Patients who are pregnant or lactating or unwilling to take contraceptive measures during the trial\n7. Patients with other behaviors that may increase the risk of illness, such as alcohol and drug abuse\n8. Patients who are unwilling or incapable to provide informed consents","ALL","18 Years","70 Years",{"count":99,"type":100},330,"ESTIMATED","INTERVENTIONAL",[103],"PHASE4","The study aimed to compare the efficacy and safety of dual and quadruple regimens with different durations (7-day, 10-day, 14-day) for the eradication of Helicobacter pylori. Subjects were randomized to receive the intervention and were reviewed by 13C-urea breath test after 6 weeks. The eradication rates, adverse reaction rates and patient adherence were calculated.",[106],"HELICOBACTER PYLORI INFECTIONS","2024-12-10",{"date":109,"type":110},"2024-12-11","ACTUAL",{"date":107,"type":110},{"date":113,"type":100},"2025-11-30",{"name":5,"class":6},1]